Home>Media>Newsroom Media Newsroom - 2025 Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines 25 MAR 2025 | READ MORE Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) 20 MAR 2025 | READ MORE Glenmark Pharma Expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India 12 MAR 2025 | READ MORE Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC) 10 MAR 2025 | READ MORE Glenmark Nutrition Awards 2025: Celebrating Innovation, Impact, and Sustainability in the Fight Against Malnutrition in India 07 MAR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches acquires and launches Acetylcysteine Injection 6 gm-30 mL (200 mg-mL) Single-Dose Vials 03 MAR 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial 27 FEB 2025 | READ MORE Glenmark Pharma reports consolidated revenue growth of 35.1%, EBITDA margin of 17.7% and PAT margin of 10.3% YoY for Q3 FY2025 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution 0.005% 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% 12 FEB 2025 | READ MORE Cosmo and Glenmark Announce UK MHRA Approval of Winlevi® for Treatment of Acne 10 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules 21 JAN 2025 | READ MORE Year – 2025 Year – 2024 Year – 2023 Year – 2022 Year – 2021 Year – 2020 Year – 2019 Year – 2018 Year – 2017 Year – 2016 Year – 2015
